{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T10:01:03Z","timestamp":1719223263195},"reference-count":22,"publisher":"American Society of Consultant Pharmacists","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2013,7,1]]},"DOI":"10.4140\/tcp.n.2013.455","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T01:04:57Z","timestamp":1373331897000},"page":"455-462","source":"Crossref","is-referenced-by-count":8,"title":["Bullous Pemphigoid: Corticosteroid Treatment and Adverse Effects in Long-Term Care Patients"],"prefix":"10.4140","volume":"28","author":[{"given":"Justin","family":"Spidey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann Marie","family":"Nye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2013,7,8]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.det.2011.06.003","article-title":"Evidence-based management of bullous pemphigoid","volume":"29","author":"BS Daniel","year":"2011","journal-title":"Dermatol Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group","volume":"131","author":"P Bernard","year":"1995","journal-title":"Arch Dermatol"},{"key":"3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archderm.131.8.957","article-title":"Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany","volume":"131","author":"D Zillikens","year":"1995","journal-title":"Arch Dermatol"},{"key":"4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2133.1994.tb13108.x","article-title":"Acquired bullous diseases of childhood: re-evaluation of diagnosis by indirect immunofluorescence examination on 1 M NaCl split skin and immunoblotting","volume":"130","author":"G Kirtschig","year":"1994","journal-title":"Br J Dermatol"},{"key":"5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study","volume":"161","author":"G Marazza","year":"2009","journal-title":"Br J Dermatol"},{"key":"6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study","volume":"337","author":"SM Langan","year":"2008","journal-title":"BMJ"},{"key":"7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1365-2133.2002.04835.x","article-title":"Guidelines for the management of bullous pemphigoid","volume":"147","author":"F Wojnarowska","year":"2002","journal-title":"Br J Dermatol"},{"key":"8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"P Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002292.pub3","article-title":"Interventions for bullous pemphigoid","author":"G Kirtschig","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoidsnew mechanisms for old drugs","volume":"353","author":"T Rhen","year":"2005","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study","volume":"129","author":"P Joly","year":"2009","journal-title":"J Invest Dermatol"},{"key":"12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1993.01680220061016","article-title":"Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid","volume":"129","author":"JC Guillaume","year":"1993","journal-title":"Arch Dermatol"},{"key":"13","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid","volume":"143","author":"S Beissert","year":"2007","journal-title":"Arch Dermatol"},{"issue":"8401","key":"14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0140-6736(84)92565-0","article-title":"Plasma exchange in bullous pemphigoid","volume":"324","author":"JC Roujeau","year":"1984","journal-title":"Lancet"},{"key":"15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","article-title":"Nicotinamide and tetracycline therapy of bullous pemphigoid","volume":"130","author":"DP Fivenson","year":"1994","journal-title":"Arch Dermatol"},{"key":"16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11882-007-0029-8","article-title":"Sulfonamide allergy and cross-reactivity","volume":"7","author":"C Brackett","year":"2007","journal-title":"Curr Allergy Asthma Rep"},{"key":"17","unstructured":"Hydrochlorothiazide. In DRUGDEXR System [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. Updated periodically."},{"key":"18","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"AV Chobanian","year":"2003","journal-title":"JAMA"},{"key":"19","unstructured":"FRAX. World Health Organization Fracture Risk Assessment Tool. Available at http:\/\/www.shef.ac.uk\/FRAX\/. Accessed November 2, 2012. <a target=\"_blank\" href='http:\/\/www.shef.ac.uk\/FRAX\/'>http:\/\/www.shef.ac.uk\/FRAX\/<\/a>"},{"key":"20","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"JM Grossman","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"21","unstructured":"Drug Facts and Comparisons. St. Louis, MO: Facts and Comparisons; 1889-98."},{"key":"22","unstructured":"Drug Topics Red Book. Thomson Reuters; 2010."}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T15:55:22Z","timestamp":1498060522000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2013\/00000028\/00000007\/art00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,1]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7,1]]}},"alternative-id":["YW377467P55L1235"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2013.455","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7,1]]}}}